These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31998298)

  • 1. The Interferon-Gamma +874 A/T Polymorphism Is Not Associated With CMV Infection After Kidney Transplantation.
    Santiago JL; Pérez-Flores I; Sánchez-Pérez L; Moreno de la Higuera MA; Calvo-Romero N; Querol-García J; Culebras E; Urcelay E; Fernández-Pérez C; Sánchez-Fructuoso AI
    Front Immunol; 2019; 10():2994. PubMed ID: 31998298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
    Luan FL
    Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients.
    Vu D; Shah T; Ansari J; Sakharkar P; Yasir Q; Naraghi R; Hutchinson I; Min D
    Transpl Infect Dis; 2014 Oct; 16(5):724-32. PubMed ID: 25208755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.
    Puttarajappa C; Bhattarai M; Mour G; Shen C; Sood P; Mehta R; Shah N; Tevar AD; Humar A; Wu C; Hariharan S
    Clin Transplant; 2016 Sep; 30(9):1159-64. PubMed ID: 27423138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
    Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation.
    De Gracia-Guindo MDC; Ruiz-Fuentes MDC; Galindo-Sacristán P; Osorio-Moratalla JM; Ruiz-Fuentes N; Rodriguez Granger J; Osuna-Ortega A
    Transplant Proc; 2018 Mar; 50(2):578-580. PubMed ID: 29579857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM; Marquez MA; Bazerbachi F; Schiff JR; Cattral MS; McGilvray ID; Norgate A; Selzner M; Rotstein C; Husain S
    Clin Transplant; 2013; 27(4):503-9. PubMed ID: 23731387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
    Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Aquaporin3 Promoter Polymorphism -1431 A/G is Associated with Acute Graft Rejection and Cytomegalovirus Infection in Kidney Recipients Due to Altered Immune Cell Migration.
    Rump K; Rahmel T; Rustige AM; Unterberg M; Nowak H; Koos B; Schenker P; Viebahn R; Adamzik M; Bergmann L
    Cells; 2020 Jun; 9(6):. PubMed ID: 32521638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
    Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
    J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
    Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
    Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Kidney Transplant Recipients With a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections.
    Parajuli S; Muth BL; Turk JA; Astor BC; Mohammed M; Mandelbrot DA; Djamali A
    Transplantation; 2016 Mar; 100(3):655-61. PubMed ID: 26760571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.